Speaking as an enthusiast, it does seem like there will be a shift from certain drugs being manufactured by a pharmaceuticals producer to self-manufacture from mRNA sequence delivery. I wonder what it means for pharmaceutical companies that have IP for, say insulin, but someone else claims control of the mRNA code that triggers it's production?